Innovent’s Tyvyt edges out PD-1s on China’s 2020 reimbursement list

The widely anticipated release of negotiated additions to the National Reimbursement Drug List by China’s National Medical Insurance Administration came on Nov. 28, with Innovent’s Tyvyt the lone anti-PD-1 mAb to make the cut. In all, 97 drugs were added to the list, including 74 drugs that aren’t traditional Chinese medicines.

Across the 52 newly-added innovative molecules to the NRDL, the average price cut was

Read the full 655 word article

User Sign In